Cargando…

Treatment with Geranylgeranylacetone Induces Heat Shock Protein 70 and Attenuates Neonatal Hyperoxic Lung Injury in a Model of Bronchopulmonary Dysplasia

PURPOSE: Bronchopulmonary dysplasia (BPD) is a respiratory complication characterized by abnormal alveolar development in premature infants. Geranylgeranylacetone (GGA) can induce heat shock protein (HSP) 70, which has cytoprotective effects against various stressors. Here, we investigated whether G...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tokuriki, Shuko, Igarashi, Aiko, Okuno, Takashi, Ohta, Genrei, Naiki, Hironobu, Ohshima, Yusei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522658/ https://www.ncbi.nlm.nih.gov/pubmed/28447205 http://dx.doi.org/10.1007/s00408-017-0007-4

Ejemplares similares

Carboxyhemoglobin Formation in Preterm Infants Is Related to the Subsequent Development of Bronchopulmonary Dysplasia
por: Tokuriki, Shuko, et al.
Publicado: (2015)

Risk Factors for the Development of Refeeding Syndrome-Like Hypophosphatemia in Very Low Birth Weight Infants
por: Igarashi, Aiko, et al.
Publicado: (2017)

Postnatal Changes in Humerus Cortical Bone Thickness Reflect the Development of Metabolic Bone Disease in Preterm Infants
por: Tokuriki, Shuko, et al.
Publicado: (2016)

Heat shock protein 70 protects the lungs from hyperoxic injury in a neonatal rat model of bronchopulmonary dysplasia
por: Lee, Cheng-Han, et al.
Publicado: (2023)

Geranylgeranylacetone attenuates hepatic fibrosis by increasing the expression of heat shock protein 70
por: HE, WEI, et al.
Publicado: (2015)

Design-Based Stereology of the Lung in the Hyperoxic Preterm Rabbit Model of Bronchopulmonary Dysplasia
por: Mühlfeld, Christian, et al.
Publicado: (2021)

Induction of Heat-Shock Protein 70 Expression by Geranylgeranylacetone Shows Cytoprotective Effects in Cardiomyocytes of Mice under Humid Heat Stress
por: Wang, Xiaowu, et al.
Publicado: (2014)

Heat Shock Protein-70 Levels Are Associated With a State of Oxidative Damage in the Development of Bronchopulmonary Dysplasia
por: Hsiao, Chien-Chou, et al.
Publicado: (2021)

Protective effect of geranylgeranylacetone, an inducer of heat shock protein 70, against drug-induced lung injury/fibrosis in an animal model
por: Fujibayashi, Takayoshi, et al.
Publicado: (2009)

Role of heat shock protein 22 in the protective effect of geranylgeranylacetone in response to oxidized-LDL
por: Gong, Ren, et al.
Publicado: (2019)

Geranylgeranylacetone Ameliorates Beta-Amyloid Toxicity and Extends Lifespan via the Heat Shock Response in Caenorhabditis elegans
por: Mossiah, Isiah, et al.
Publicado: (2022)

Geranylgeranylacetone selectively binds to the HSP70 of Helicobacter pylori and alters its coccoid morphology
por: Grave, Ewa, et al.
Publicado: (2015)

Suppression of Alzheimer's disease-related phenotypes by the heat shock protein 70 inducer, geranylgeranylacetone, in APP/PS1 transgenic mice via the ERK/p38 MAPK signaling pathway
por: Sun, Yuan, et al.
Publicado: (2017)

Infant with right hemiplegia due to acute encephalopathy with biphasic seizures and late reduced diffusion (AESD): A case report
por: Takahashi, Ai, et al.
Publicado: (2021)

NOVEL BIOMARKERS OF BRONCHOPULMONARY DYSPLASIA AND BRONCHOPULMONARY DYSPLASIA-ASSOCIATED PULMONARY HYPERTENSION
por: Sahni, Mitali, et al.
Publicado: (2020)

GERANYLGERANYLACETONE ATTENUATES CISPLATIN-INDUCED REDUCTIONS IN CELL VIABILITY BY SUPPRESSING THE ELEVATION OF INTRACELLULAR P53 CONTENT WITHOUT HEAT SHOCK PROTEIN INDUCTION
por: HASEGAWA, MOTOFUSA, et al.
Publicado: (2012)

Phenotypes of Bronchopulmonary Dysplasia
por: Wang, Shih-Hsin, et al.
Publicado: (2020)

Suppression of Alzheimer’s Disease-Related Phenotypes by Geranylgeranylacetone in Mice
por: Hoshino, Tatsuya, et al.
Publicado: (2013)

The Cytotoxic Effects of Geranylgeranylacetone Are Attenuated in the High-Glucose Condition
por: Nakano, Yuko, et al.
Publicado: (2019)

Pulmonary Biomarkers of Bronchopulmonary Dysplasia
por: Thompson, Alecia, et al.
Publicado: (2008)

Incidence of Bronchopulmonary Dysplasia in Korea
por: Choi, Chang Won, et al.
Publicado: (2012)

Oxidative Stress and Bronchopulmonary Dysplasia
por: Perrone, Serafina, et al.
Publicado: (2012)

Present and Future of Bronchopulmonary Dysplasia
por: Bonadies, Luca, et al.
Publicado: (2020)

Perspectives on Probiotics and Bronchopulmonary Dysplasia
por: Yang, Kun, et al.
Publicado: (2020)

Pulmonary hypertension in bronchopulmonary dysplasia
por: Hansmann, Georg, et al.
Publicado: (2020)

Bronchopulmonary Dysplasia: Pathogenesis and Pathophysiology
por: Dankhara, Nilesh, et al.
Publicado: (2023)

Expression of Heat Shock Protein 70 in Oral Epithelial Dysplasia and Oral Squamous Cell Carcinoma: An Immunohistochemical Study
por: Priyanka, K. P., et al.
Publicado: (2019)

The Hyperoxic-Hypoxic Paradox
por: Hadanny, Amir, et al.
Publicado: (2020)

Pulmonary hypertension in infants with bronchopulmonary dysplasia
por: Kim, Gi Beom
Publicado: (2010)

Pulmonary Hemosiderosis in Children with Bronchopulmonary Dysplasia
por: Kurahara, David, et al.
Publicado: (2014)

Biomarkers for Bronchopulmonary Dysplasia in the Preterm Infant
por: Rivera, Lidys, et al.
Publicado: (2016)

Hospital management of severe bronchopulmonary dysplasia
por: Moretti, Corrado, et al.
Publicado: (2015)

Correlation of Retinopathy of Prematurity with Bronchopulmonary Dysplasia
por: Podraza, Wojciech, et al.
Publicado: (2018)

The rate and pattern of bronchopulmonary dysplasia in Kuwait
por: Al-Essa, Mazen, et al.
Publicado: (2004)

Impact of bronchopulmonary dysplasia on brain and retina
por: Poon, Annie Wing Hoi, et al.
Publicado: (2016)

Strategies to improve outcomes of bronchopulmonary dysplasia
por: Jung, Young Hwa, et al.
Publicado: (2019)

New Pharmacologic Approaches to Bronchopulmonary Dysplasia
por: Roberts, Katelyn, et al.
Publicado: (2021)

An Update on the Prevention and Management of Bronchopulmonary Dysplasia
por: Hennelly, Marissa, et al.
Publicado: (2021)

Patho-mechanisms of the origins of bronchopulmonary dysplasia
por: Sahni, Mitali, et al.
Publicado: (2021)

Pharmacotherapy in Bronchopulmonary Dysplasia: What Is the Evidence?
por: Sakaria, Rishika P., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7ounve6qm2pao4r9m9jjomlrq7